Clinical Trials Logo

Clinical Trial Summary

Reversible Cerebral Vasoconstriction Syndrome (RCVS) is a syndrome described at the end of the 20th century. Generally, it has a benign course. It is revealed by acute headaches, in different circumstances such as sexual activity, physical exertion or emotional disturbances. But, in few cases, it might be complicated by seizure, stroke and subarachnoid haemorrhage. The diagnosis is confirmed on radiological examination, which shows diffuse cerebral vasoconstriction of brain vessel. It calls reversible because at three month, vasoconstriction disappears. Most cases occur during post partum or after serotoninergic/adrenergic drug use. The pathophysiology is unknown but a transient disturbance in the control of cerebrovascular tone by sympathic hyperactivity and/or endothelial dysfunction are suspected. The assessment of endothelial dysfunction in brain is possible with transcranial doppler. Chen et al. showed an impairment of vasodilatation post apnea induced called BHI on RCVS subjects compared with healthy control. BHI is a reflect of endothelial function in brain. Currently, investigators do not know if endothelial dysfunction occurred only in brain or if it may occur in systemic vessel. Some case reports talk about systemic complication such as kidney infarct or hepatic arterial vasospasm so a systemic vascular dysfunction may be suspected. In this study, researchers will study systemic endothelial function by measure of the pulse wave velocity during RCVS and after its recovering at 3 months, and compare it at healthy controls.


Clinical Trial Description

The investigators lead a case control study to find a systemic endothelial dysfunction by the using of Complior device. Complior is a mechanographer who calculates pulse wave velocity (PWV). Pulse wave velocity is a reflect of arterial stiffness and it's correlate with endothelial dysfunction. For BHI, a Philips echograph is used before and after 30 second of breath holding. Study protocol is : For Patient : - Day 0 : in hospital : anamnesis, medical history, physic examination, EKG, blood sample analysis, BHI, PWV analysis - Month 1 : in medical visit : medical evolution, physic examination, EKG, blood sample analysis, BHI, PWV analysis - Month 3 : in medical visit : medical evolution, physic examination, EKG, blood sample analysis, BHI, PWV analysis, cerebral angioCT Scan For control : - Day 0 : in hospital : medical history, physic examination, EKG, BHI, PWV analysis ;


Study Design


Related Conditions & MeSH terms

  • Reversible Cerebral Vasoconstriction Syndrome
  • Syndrome

NCT number NCT04463212
Study type Observational
Source Nantes University Hospital
Contact
Status Completed
Phase
Start date January 29, 2021
Completion date January 12, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT03509701 - Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus
Not yet recruiting NCT02756416 - Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome N/A
Withdrawn NCT03150524 - RCVS: The Rational Approach to Diagnosis and Treatment Phase 4
Recruiting NCT04179383 - Triggers And Risk Factors to Develop a Reversible Cerebral Vasoconstriction Syndrome N/A
Withdrawn NCT04580238 - Onabotulinum Toxin A (Botox) for the Treatment of Persistent Post-Stroke and Vascular Headache Phase 1
Recruiting NCT05491980 - Florida Cerebrovascular Disease Biorepository and Genomics Center